We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+5.63%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$406M
AUM Growth
-$32.3M
Cap. Flow
-$129M
Cap. Flow %
-31.86%
Top 10 Hldgs %
49.27%
Holding
151
New
39
Increased
19
Reduced
25
Closed
51

Sector Composition

Rank Sector Weight
1 Healthcare 76.27%
2 Miscellaneous 10.9%
3 Technology 4.09%
4 Consumer Discretionary 3.5%
5 Industrials 2.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCYC
26
DELISTED
PHARMACYCLICS INC
PCYC
$4.49M 1.11%
+50,000
New +$4.69M
TW
27
DELISTED
TOWERS WATSON & CO COM STK CL A (DE)
TW
$4.35M 1.07%
+41,740
New +$4.56M
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$4.35M 1.07%
105,000
+65,000
+163% +$3.35M
GILD icon
29
Gilead Sciences
GILD
$186B
$4.15M 1.02%
50,000
-44,000
-47% -$3.42M
INCY icon
30
Incyte
INCY
$25.6B
$4.12M 1.02%
73,000
-10,000
-12% -$511K
PTCT icon
31
PTC Therapeutics
PTCT
$5.66B
$3.92M 0.97%
+150,000
New +$3.21M
EPZM
32
DELISTED
Epizyme, Inc
EPZM
$3.52M 0.87%
+113,188
New +$2.67M
CL icon
33
Colgate-Palmolive
CL
$69.6B
$3.26M 0.8%
47,799
-15,000
-24% -$1.01M
AN icon
34
AutoNation
AN
$5.76B
$3.14M 0.77%
+52,600
New +$2.91M
BRCM
35
DELISTED
BROADCOM CORP CL-A
BRCM
$2.94M 0.72%
79,120
-33,380
-30% -$1.09M
CSTE icon
36
Caesarstone
CSTE
$97.2M
$2.92M 0.72%
59,600
+51,770
+661% +$2.63M
AERI
37
DELISTED
Aerie Pharmaceuticals
AERI
$2.73M 0.67%
110,000
-2,500
-2% -$43.3K
TTPH
38
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.67M 0.66%
+9,900
New +$2.12M
AMPE
39
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$2.6M 0.64%
1,040
+290
+39% +$592K
RCPT
40
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.56M 0.63%
+60,000
New +$2.07M
MGNX icon
41
MacroGenics
MGNX
$260M
$2.41M 0.59%
111,000
+70,000
+171% +$1.47M
EIGR
42
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.4M 0.59%
+333
New +$1.67M
CASC
43
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.39M 0.59%
123,056
BKNG icon
44
Booking.com
BKNG
$128B
$2.32M 0.57%
48,300
-7,750
-14% -$372K
VNDA icon
45
Vanda Pharmaceuticals
VNDA
$306M
$2.27M 0.56%
140,000
+75,000
+115% +$999K
ATNM icon
46
Actinium Pharmaceuticals
ATNM
$37.1M
$2.17M 0.53%
+10,000
New +$3.33M
AKBA icon
47
Akebia Therapeutics
AKBA
$242M
$2.02M 0.5%
+72,500
New +$1.75M
GILD icon
48
CALL
Gilead Sciences
GILD
$186B
$2.01M 0.49%
2,000
IMMU
49
DELISTED
Immunomedics Inc
IMMU
$2.01M 0.49%
550,000
+250,000
+83% +$918K
TRVN
50
DELISTED
Trevena, Inc.
TRVN
$1.93M 0.47%
546
+146
+37% +$456K

Similar funds

Sphera Funds Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sphera Funds Management held 151 positions worth $406M, down 7.4% from $438M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sphera Funds Management withdrew a net $129M in Q2 2014, closing 51 positions and reducing 25 holdings. Its most notable exit was State Street Financial Select Sector SPDR ETF, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 75% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Shire pic worth $14.1M.

  • Sphera Funds Management's largest Q2 2014 buy was Shire pic: 180,000 shares worth $14.1M.
  • Sphera Funds Management added most to Teva Pharmaceutical Industries Limited in Q2 2014, an estimated $19.6M increase.
  • Sphera Funds Management's biggest Q2 2014 reduction was Summit Financial Group, Inc., cutting an estimated $116M.
  • Sphera Funds Management fully exited State Street Financial Select Sector SPDR ETF in Q2 2014, selling an estimated $15.2M.
  • Sphera Funds Management's ten largest holdings make up 49% of its $406M portfolio in Q2 2014.
  • Sphera Funds Management opened 39 new positions and closed 51 in Q2 2014.
  • Sphera Funds Management's portfolio value fell 7.4% quarter-over-quarter to $406M.

Based on Sphera Funds Management's 13F filing for Q2 2014, filed 11 Aug 2014.